Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Neil A. Bailey, Renata Walewska(Dorset HealthCare University NHS Foundation Trust), Matthew R. Wilson(Beatson West of Scotland Cancer Centre), Lori A. Leslie(Hackensack University Medical Center), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Richard R. Furman(Cornell University), Elise A. Chong(Hospital of the University of Pennsylvania), Jennifer R. Brown(Dana-Farber Cancer Institute), Talha Munir(Leeds Teaching Hospitals NHS Trust), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Craig A. Portell(University of Virginia), Amanda N. Seddon(Rush University Medical Center), Harriet S. Walter(Leicester Royal Infirmary), John N. Allan(Cornell University), Guilherme Fleury Perini(Hospital Israelita Albert Einstein), Jeffrey J. Pu(SUNY Upstate Medical University), Adrian Wiestner(National Institutes of Health), Scott F. Huntington(Yale Cancer Center), Ryan Jacobs(Levine Cancer Institute), Lotta Hanson(Karolinska Institutet), Krish Patel, Nicolás Martínez‐Calle(Nottingham University Hospitals NHS Trust), Darko Antić(University of Belgrade), Mark B. Geyer(Memorial Sloan Kettering Cancer Center), Michael Koropsak(Hackensack University Medical Center), Krista M. Isaac, Danielle M. Brander(Duke University), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Helen Parry(University of Birmingham), Piers Patten, Erlene Seymour(Wayne State University), Anders Österborg(Karolinska University Hospital), Mazyar Shadman(University of Washington), Inhye E. Ahn(Dana-Farber Cancer Institute), Paul M. Barr(University of Rochester Medical Center), Nikita Malakhov(NewYork–Presbyterian Hospital), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Meera Patel(Wayne State University), Matthew S. Davids(Dana-Farber Cancer Institute), Christine E. Ryan(Dana-Farber Cancer Institute), Daniel Wojenski(Northwestern University), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Dima El‐Sharkawi(Royal Marsden Hospital), John M. Pagel, Manali Kamdar(University of Colorado Cancer Center), Angus Broom(Western General Hospital), Ellin Berman(Memorial Sloan Kettering Cancer Center)
Cited by 318
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k